{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:50:11Z","timestamp":1792759811381,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years Janus kinase inhibitors (JAKi) have joined tumor necrosis factor inhibitors (TNFi) and interleukin (IL)-17 inhibitors (IL-17i) as approved disease modifying anti-rheumatic drugs (DMARD) for moderate to severe forms of axial spondyloarthritis (axSpA). Drug survival in axSpA patients has not been well studied in a real-world outpatient scenario since the approval of JAKi. We aimed to analyze the three drug classes based on modes of actions (MoA) for their persistence rates among German axSpA outpatients. A retrospective analysis of the RHADAR database for axSpA patients with a new initiation of TNFi, IL-17i, or JAKi treatment between January 2015 and October 2023 was conducted. Analyses included Kaplan-Meier curves and adjusted Cox regressions for drug discontinuation. 1222 new biological DMARD (TNFi [<jats:italic>n<\/jats:italic>\u2009=\u2009954], IL-17i [<jats:italic>n<\/jats:italic>\u2009=\u2009190]) or JAKi (<jats:italic>n<\/jats:italic>\u2009=\u200978) treatments were reported. The median drug survival was 31 months for TNFi, 25 for IL-17i, and 18 for JAKi. The corresponding 2-year drug survival rate was 79.6%, 72.6%, and 62.8% for TNFi, IL-17i, and JAKi, respectively. The probability for discontinuation for JAKi was significantly higher compared with TNFi (HR 1.91 [95% CI 1.22\u20132.99]) as well as for IL-17i compared with TNFi (HR 1.43 [95% CI 1.02\u20132.01]), possibly related to more frequent use of TNFis as first-line therapy. IL-17i and JAKi discontinuation probabilities were similar. Primary non-response was the reason for drug discontinuation in most cases across all MoA. TNFi treatment might persist longer than JAKi and IL-17i in German axSpA outpatients, possibly related to more severe or refractory disease in patients with JAKi-treated or IL-17i-treated axSpA.<\/jats:p>","DOI":"10.1007\/s00296-024-05671-9","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T07:02:15Z","timestamp":1723532535000},"page":"2057-2066","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-7074","authenticated-orcid":false,"given":"Patrick-Pascal","family":"Strunz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0228-7183","authenticated-orcid":false,"given":"Matthias","family":"Englbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4105-6064","authenticated-orcid":false,"given":"Linus Maximilian","family":"Risser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-0267","authenticated-orcid":false,"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-3903","authenticated-orcid":false,"given":"Matthias","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-2299","authenticated-orcid":false,"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-4459","authenticated-orcid":false,"given":"Michael","family":"Gernert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-9699","authenticated-orcid":false,"given":"Astrid","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8084-4497","authenticated-orcid":false,"given":"Peter","family":"Bartz-Bazzanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-7174","authenticated-orcid":false,"given":"Cay","family":"von der Decken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1362-7326","authenticated-orcid":false,"given":"Kirsten","family":"Karberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2132-8369","authenticated-orcid":false,"given":"Georg","family":"Gauler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2471-1411","authenticated-orcid":false,"given":"Patrick","family":"Wurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8124-2111","authenticated-orcid":false,"given":"Susanna","family":"Sp\u00e4thling-Mestekemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0538-1717","authenticated-orcid":false,"given":"Christoph","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-5560","authenticated-orcid":false,"given":"Wolfgang","family":"Vorbr\u00fcggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5382-3014","authenticated-orcid":false,"given":"Johannes","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1856-3085","authenticated-orcid":false,"given":"Martin","family":"Welcker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2588-7547","authenticated-orcid":false,"given":"Stefan","family":"Kleinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"8","key":"5671_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41584-022-00789-1","volume":"18","author":"WP Maksymowych","year":"2022","unstructured":"Maksymowych WP, Lambert RGW, Caplan L, van den Bosch FE, \u00d8stergaard M (2022) Improving the design of RCTs in non-radiographic axial spondyloarthritis. Nat Rev Rheumatol 18(8):481\u2013489. https:\/\/doi.org\/10.1038\/s41584-022-00789-1Epub 2022 May 13. PMID: 35562426","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"5671_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjd.13343","volume":"172","author":"R Gniadecki","year":"2015","unstructured":"Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L (2015) Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 172(1):244\u2013252. https:\/\/doi.org\/10.1111\/bjd.13343Epub 2014 Nov 30. PMID: 25132294","journal-title":"Br J Dermatol"},{"key":"5671_CR3","doi-asserted-by":"publisher","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Rosen\u00f8 NAL, Aagaard D, L\u00f8rup EH, Nielsen ML, Nymand L et al (2022) Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum 53:151979 Epub 2022 Feb 9. PMID: 35183936","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"5671_CR4","doi-asserted-by":"publisher","first-page":"e28164","DOI":"10.2196\/28164","volume":"23","author":"S Kleinert","year":"2021","unstructured":"Kleinert S, Bartz-Bazzanella P, von der Decken C, Knitza J, Witte T, Fekete SP et al (2021) A Real-World Rheumatology Registry and Research Consortium: the German RheumaDatenRhePort (RHADAR) Registry. J Med Internet Res 23(5):e28164. https:\/\/doi.org\/10.2196\/28164PMID: 34014170; PMCID: PMC8176344","journal-title":"J Med Internet Res"},{"key":"5671_CR5","doi-asserted-by":"publisher","unstructured":"Baraliakos X, Kiltz U, Kononenko I, Ciurea A (2023) Treatment overview of axial spondyloarthritis in 2023. Best Pract Res Clin Rheumatol 37(3):101858. https:\/\/doi.org\/10.1016\/j.berh.2023.101858. Epub 2023 Sep 5. PMID: 37673758","DOI":"10.1016\/j.berh.2023.101858"},{"issue":"4","key":"5671_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","volume":"18","author":"A Danve","year":"2022","unstructured":"Danve A, Deodhar A (2022) Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol 18(4):205\u2013216. https:\/\/doi.org\/10.1038\/s41584-022-00761-zEpub 2022 Mar 10. PMID: 35273385","journal-title":"Nat Rev Rheumatol"},{"key":"5671_CR7","doi-asserted-by":"publisher","unstructured":"Yu CL, Yang CH, Chi CC (2020) Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence. BioDrugs 34(5):669\u2013679. https:\/\/doi.org\/10.1007\/s40259-020-00442-x. PMID: 32946076","DOI":"10.1007\/s40259-020-00442-x"},{"issue":"1","key":"5671_CR8","doi-asserted-by":"publisher","first-page":"e003942","DOI":"10.1136\/rmdopen-2023-003942","volume":"10","author":"M Dougados","year":"2024","unstructured":"Dougados M, Lardy-Cl\u00e9aud A, Desfleurs E, Claudepierre P, Goupille P, Ryussen-Witrand A et al (2024) Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study. RMD Open 10(1):e003942. https:\/\/doi.org\/10.1136\/rmdopen-2023-003942PMID: 38428974; PMCID: PMC10910420","journal-title":"RMD Open"},{"issue":"5","key":"5671_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/acr.24523","volume":"74","author":"B Glintborg","year":"2022","unstructured":"Glintborg B, Lindstr\u00f6m U, Giuseppe DD, Provan SA, Gudbjornsson B, Hetland ML et al (2022) One-year treatment outcomes of Secukinumab Versus Tumor necrosis factor inhibitors in Spondyloarthritis: results from five nordic Biologic registries Including more than 10,000 treatment courses. Arthritis Care Res (Hoboken) 74(5):748\u2013758. https:\/\/doi.org\/10.1002\/acr.24523Epub 2022 Mar 8. PMID: 33253491","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5671_CR10","doi-asserted-by":"publisher","first-page":"815881","DOI":"10.3389\/fmed.2021.815881","volume":"8","author":"A Garc\u00eda-Dorta","year":"2022","unstructured":"Garc\u00eda-Dorta A, Le\u00f3n-Suarez P, Pe\u00f1a S, Hern\u00e1ndez-D\u00edaz M, Rodr\u00edguez-Lozano C, Gonz\u00e1lez-D\u00e1vila E et al (2022) Association of Gender, diagnosis, and obesity with Retention Rate of Secukinumab in Spondyloarthropathies: results form a Multicenter Real-World Study. Front Med (Lausanne) 8:815881. https:\/\/doi.org\/10.3389\/fmed.2021.815881PMID: 35096907; PMCID: PMC8792854","journal-title":"Front Med (Lausanne)"},{"key":"5671_CR11","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-Cruz B, Otero-Varela L, Freire-Gonz\u00e1lez M, Busquets-P\u00e9rez N, Garc\u00eda Gonz\u00e1lez AJ, Moreno-Ramos M et al (2024) Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry. https:\/\/doi.org\/10.1136\/ard-2023-225271. Epub ahead of print. PMID: 38594056 Ann Rheum Dis ard-2023-225271","DOI":"10.1136\/ard-2023-225271"},{"key":"5671_CR12","unstructured":"UCB (2023) https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-Receives-New-European-Commission-Approvals-for-BIMZELXRVbimekizumab-for-the-Treatment-of-Psoriatic-Arthritis-and-Axial-Spondyloarthritis. Accessed June 23, 2024"},{"key":"5671_CR13","doi-asserted-by":"publisher","first-page":"1395968","DOI":"10.3389\/fimmu.2024.1395968","volume":"15","author":"PP Strunz","year":"2024","unstructured":"Strunz PP, Englbrecht M, Risser LM, Witte T, Froehlich M, Schmalzing M et al (2024) Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12\/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database. Front Immunol 15:1395968. https:\/\/doi.org\/10.3389\/fimmu.2024.1395968PMID: 38846940; PMCID: PMC11153701","journal-title":"Front Immunol"},{"key":"5671_CR14","doi-asserted-by":"publisher","unstructured":"Kiltz U, Braun J, DGRh, Becker A, Chenot DEGAM et al (2019) JF, Long version on the S3 guidelines for axial spondyloarthritis including Bechterew\u2019s disease and early forms, Update 2019: Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies an. Z Rheumatol 78(Suppl 1):3\u201364. German. https:\/\/doi.org\/10.1007\/s00393-019-0670-3. PMID: 31784900","DOI":"10.1007\/s00393-019-0670-3"},{"key":"5671_CR15","volume-title":"A language and environment for statistical computing","author":"R Team","year":"2018","unstructured":"Team R, Core R (2018) A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"key":"5671_CR16","volume-title":"RStudio: Integrated Development for R","author":"Team RStudio","year":"2016","unstructured":"Team RStudio (2016) RStudio: Integrated Development for R. RStudio, Inc, Boston, MA"},{"issue":"9","key":"5671_CR17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/14740338.2021.1924146","volume":"20","author":"JG Letarouilly","year":"2021","unstructured":"Letarouilly JG, Salmon JH, Flipo RM (2021) Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review. Expert Opin Drug Saf 20(9):1087\u20131094 Epub 2021 May 14. PMID: 33926364","journal-title":"Expert Opin Drug Saf"},{"key":"5671_CR18","doi-asserted-by":"crossref","unstructured":"D\u2019Amico ME, Silvagni E, Carrara G, Zanetti A, Govoni M, Scir\u00e8 CA et al (2021) Role of comorbidities on therapeutic persistence of biological agents in rheumatoid arthritis: results from the RECord-linkage On Rheumatic Disease study on administrative healthcare databases. Scand J Rheumatol 50(5):333\u2013342. doi: 10.1080\/03009742.2020.1855365. Epub 2021 Mar 4. PMID: 33660559","DOI":"10.1080\/03009742.2020.1855365"},{"issue":"9","key":"5671_CR19","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1136\/ard.2007.072397","volume":"66","author":"MK de Vries","year":"2007","unstructured":"de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA et al (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66(9):1252\u20131254. https:\/\/doi.org\/10.1136\/ard.2007.072397Epub 2007 May 1. PMID: 17472991; PMCID: PMC1955152","journal-title":"Ann Rheum Dis"},{"key":"5671_CR20","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Guijo VC, Cravo AR, Castro Mdel C, Font P, Mu\u00f1oz-Gomariz E, Collantes-Estevez E (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74(3):254-8. https:\/\/doi.org\/10.1016\/j.jbspin.2006.08.005. Epub 2007 Mar 1. PMID: 17387031","DOI":"10.1016\/j.jbspin.2006.08.005"},{"issue":"5","key":"5671_CR21","first-page":"661","volume":"28","author":"S Arends","year":"2010","unstructured":"Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E et al (2010) The formation of autoantibodies and antibodies to TNF-\u03b1 blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(5):661\u2013668 Epub 2010 Oct 22. PMID: 20822711","journal-title":"Clin Exp Rheumatol"},{"key":"5671_CR22","doi-asserted-by":"crossref","unstructured":"Albrecht K, Marschall U, Callhoff J (2021) Prescription of analgesics in patients with rheumatic diseases in Germany: A claims data analysis. Z Rheumatol 80(Suppl 2):68\u201375. doi: 10.1007\/s00393-021-00971-y. Epub 2021 Apr 7. PMID: 33825975; PMCID: PMC8752520","DOI":"10.1007\/s00393-021-00971-y"},{"issue":"11","key":"5671_CR23","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00296-018-4124-z","volume":"38","author":"K Kr\u00fcger","year":"2018","unstructured":"Kr\u00fcger K, von Hin\u00fcber U, Meier F, Tian H, B\u00f6hm K, Jugl SM et al (2018) Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatol Int 38(11):2121\u20132131. https:\/\/doi.org\/10.1007\/s00296-018-4124-zEpub 2018 Aug 9. PMID: 30094685","journal-title":"Rheumatol Int"},{"key":"5671_CR24","doi-asserted-by":"publisher","unstructured":"Haibel H, Redeker I, Zink A, Callhoff J, Marschall U et al (2019) Health care and disease burden in persons with axial spondyloarthritis in Germany. Z Rheumatol 78(9):865\u2013874. German. https:\/\/doi.org\/10.1007\/s00393-019-0650-7. PMID: 31172266","DOI":"10.1007\/s00393-019-0650-7"},{"issue":"1","key":"5671_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13075-020-02301-0","volume":"22","author":"I Redeker","year":"2020","unstructured":"Redeker I, Callhoff J, Hoffmann F, Marschall U, Haibel H, Sieper J et al (2020) The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. Arthritis Res Ther 22(1):210. https:\/\/doi.org\/10.1186\/s13075-020-02301-0PMID: 32912264; PMCID: PMC7488243","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"5671_CR26","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/s41598-024-52016-4","volume":"14","author":"G Larid","year":"2024","unstructured":"Larid G, Baudens G, Tiemdjo-Djimaffo G, Coquerelle P, Goeb V, Guyot MH et al (2024) Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network. Sci Rep 14(1):1374. https:\/\/doi.org\/10.1038\/s41598-024-52016-4PMID: 38228719; PMCID: PMC10791989","journal-title":"Sci Rep"},{"issue":"8","key":"5671_CR27","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/acr.24782","volume":"74","author":"D Sumpton","year":"2022","unstructured":"Sumpton D, Kelly A, Craig JC, Hassett G, Kane B, Oliffe M et al (2022) Preferences for Biologic treatment in patients with psoriatic arthritis: a Discrete Choice Experiment. Arthritis Care Res (Hoboken) 74(8):1234\u20131243. https:\/\/doi.org\/10.1002\/acr.24782Epub 2022 Jun 1. PMID: 34514744","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5671_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2147\/PPA.S242336","volume":"14","author":"D Aletaha","year":"2020","unstructured":"Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R et al (2020) Treatment Mode preferences in Psoriatic Arthritis: a qualitative Multi-country Study. Patient Prefer Adherence 14:949\u2013961 PMID: 32606613; PMCID: PMC7293411","journal-title":"Patient Prefer Adherence"},{"key":"5671_CR29","doi-asserted-by":"publisher","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 386(4):316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927. PMID: 35081280","DOI":"10.1056\/NEJMoa2109927"},{"key":"5671_CR30","unstructured":"EMA (2023) https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023. Accessed 28 January 2024"},{"key":"5671_CR31","doi-asserted-by":"publisher","unstructured":"Ngo MD, Zummer M, Andersen KM, Richard N (2022) First Biologic Drug Persistence in Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: A Real-World Canadian Physicians\u2019 Experience. J Clin Rheumatol 28(1):e210-e216. https:\/\/doi.org\/10.1097\/RHU.0000000000001693. PMID: 33394832","DOI":"10.1097\/RHU.0000000000001693"},{"issue":"5","key":"5671_CR32","first-page":"762","volume":"37","author":"G Lopalco","year":"2019","unstructured":"Lopalco G, Venerito V, Cantarini L, Emmi G, Salaffi F, Di Carlo M et al (2019) Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. Clin Exp Rheumatol 37(5):762\u2013767 Epub 2019 Apr 16. PMID: 31025925","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"5671_CR33","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1093\/rheumatology\/keab070","volume":"60","author":"X Michelena","year":"2021","unstructured":"Michelena X, Zhao SS, Dubash S, Dean LE, Jones GT, Marzo-Ortega H (2021) Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. Rheumatology (Oxford) 60(12):5795\u20135800. https:\/\/doi.org\/10.1093\/rheumatology\/keab070PMID: 33502476; PMCID: PMC8645273","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05671-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05671-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05671-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T02:05:17Z","timestamp":1726193117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05671-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["5671"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05671-9","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"31 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. This study was submitted to the ethics committee of the Medical Faculty of the University of Wuerzburg (DE\/EKBY13) (Date February 19th, 2024, No. 20240122 03). The ethics committee considered the study a retrospective data analysis of pseudonymzied collected clinical routine data that did not require ethical approval by German law as long as publication of data is in anonymous form. All participants provided written informed consent to be included in the RHADAR database and allow their pseudonymized data to be analyzed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"PPS received speaker\u2019s fees and travel grants from Janssen-Cilag Galapagos, Eli Lilly, Boehringer\/Ingelheim and AbbVie (less than $10,000 each) as well as research funding from Chugai (25000$). ME received payment for data analysis from RHADAR and consulting fees from Abbvie and RHADAR as well as speaker fees and honoraria for lectures from Sanofi, Swedish orphan Biovitrum and Abbvie. ME leadership or fiduciary role from Chugai. LMR declares that he has received travel and meeting support from Abbvie and Boehringer and speaking fees from Novartis. TW received honoraria for lectures from Abbvie, Amgen, BMS, Celgene, Fresenius Kabi, Galapagos, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, UCB. MF received speaker\u2019s fees, travel grants or compensation for board memberships from AbbVie, Amgen, AstraZeneca, Novartis, Janssen, Hexal, Pfizer, Takeda, UCB and Eli Lilly. MS received speaker\u2019s fees, travel grants, research funding, or compensation for consultancies or board memberships from AbbVie, Actelion, AstraZeneca, BMS, Boehringer\/Ingelheim, Celgene, Chugai\/Roche, Eli Lilly, Genzyme, Gilead, Hexal\/Sandoz, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Takeda (Shire), UCB (less than $ 10,000 each). MG received travel grants, compensation for advisory boards or speaker\u2019s fees from AbbVie, Chugai, Eli Lilly, Hexal, Janssen, Novartis, Pfizer, Takeda AS declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. PBB declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. CvdD received travel grants from Galapagos and Abbvie. KK received speaker fees from Abbvie and UCB. GG received speaker fees and travel grants from Abbvie, Janssen, Galapagos, and Lilly. PW declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. SSM received speaker fees from Abbvie, Astra Zeneca, Boerhringer-Ingelheim, BMS, Galapagos, GSK, Lilly, MSD, Novartis, Pfizer, Sanofi, UCB. CK declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. WV declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. JH declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. MW declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. SK received grants from Abbvie, Novartis, and sparrow for phase 2\/3 clinical trials and cosulting or speaker fees from Abbvie, Celgene, Chugai, Galapagos, Novartis, and Siemens Healthineers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}